MeiraGTx (MGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

MeiraGTx Holdings’ MGTX clinical bridging study of its gene therapy candidate, AAV-GAD, for treating Parkinson’s disease (PD) ...

Alec Stranahan, an analyst from Bank of America Securities, maintained the Buy rating on Meiragtx Holdings (MGTX – Research Report). The ...

On Tuesday, MeiraGTx Holdings PLC (MGTX) stock saw a modest uptick, ending the day at $5.33 which represents a slight increase of $0.69 or 14.87% from the prior close of $4.64. The stock opened at $5.

伦敦和纽约 - 临床阶段基因医学公司MeiraGTx Holdings plc (NASDAQ:MGTX)宣布其最新临床试验MGT-GAD-025取得令人鼓舞的结果。该试验旨在治疗帕金森氏症,达到了主要的安全性和耐受性目标,同时在特发性帕金森氏症患者的关键疗效终点上也显示出显著改善。

MeiraGTx Holdings (MGTX) stock gains in premarket trading after positive trial results for the company's AAV-GAD gene therapy ...

Exciting results for MeiraGTx Holdings plc's GAD gene therapy for Parkinson's Disease, with promising phase 1/2 data and ...

MeiraGTx Holdings has unveiled promising results from its clinical bridging study of AAV-GAD, a gene therapy for Parkinson’s ...

MeiraGTx Holdings plc (MGTX), a vertically integrated, clinical-stage genetic medicines company, announced Tuesday positive top-line ...

Piper Sandler重申了对MeiraGTx Holdings plc (NASDAQ: MGTX)股票的"增持"评级，目标价保持在$26.00。 尽管股价年初至今大幅下跌，但Piper Sandler认为，鉴于公司目前约$2.43亿的企业价值和潜在的大额里程碑付款，这是投资者的一个具有吸引力的入场点。

Short interest in MeiraGTx Holdings PLC (NASDAQ:MGTX) increased during the last reporting period, rising from 1.81M to 1.95M. This put 3.49% of the company's publicly available shares short.

Squarepoint Ops LLC purchased a new position in MeiraGTx Holdings plc (NASDAQ:MGTX – Free Report) during the second quarter, Holdings Channel reports. The fund purchased 29,249 shares of the ...